A Phase 1b/2, Multicenter, Open-Label Trial To Evaluate The Safety Of Talimogene Laherparepvec (T-Vec) Injected Into Primary And Metastatic Liver Tumors Alone And In Combination With Pembrolizumab (Pembro) (Masterkey-318).
JOURNAL OF CLINICAL ONCOLOGY（2018）
Abstract
TPS3105Background: Combining the intralesional oncolytic immunotherapy T-VEC with systemic immunotherapy may enhance the systemic efficacy of both agents through complementary mechanisms of action....
MoreTranslated text
Key words
metastatic liver tumors,pembrolizumab,open-label,t-vec
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined